NVCR:Novocure Ltd Snapshot | Charting | News | Options
$11.83   0.00%  $0.00 NASDAQ 7:00a ET
April 5 '24 		Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreat... BusinessWire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
     BusinessWire

    Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.

    Full Story →

    Headline News
    Novocure to Report First Quarter 2024 Financial Results
    7:00a ET April 1 '24 BusinessWire
    Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
    9:29a ET March 27 '24 BusinessWire
    METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
    7:00a ET March 27 '24 BusinessWire
    More News →
    Day  0.00%Week  5.06%Month  10.45%More Charting →
    April 22 '24. Markets Closed.
    Last $11.83
    Day change   0.00%$0.00
    Open $NA
    Gap at open $NA
    Previous close $11.83
    Trading volume 296
    10 Day avg vol. 1,023,697
    Shares out. 107.1Mil
    Market cap. $1.3Bil
    Trading activity Below Avg.
    Previous data from yesterday, April 22 '24.

    Historical Price Performance
    3 month   15.53% 
    6 month   9.14% 
    1 year   81.27% 
    2 year   85.07% 

    Earnings
    Previous 12m -$1.95
    Next 12m Estimate -$1.76
    P/E ratio 6.1x
    Revenue 509Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2024 All rights reserved.